Advertisement
Advertisement
Enzacord-40

Enzacord-40 Dosage/Direction for Use

enzalutamide

Manufacturer:

Accord Healthcare

Distributor:

Indochina Healthcare

Marketer:

Indochina Healthcare
Full Prescribing Info
Dosage/Direction for Use
Posology: The recommended dose is 160 mg enzalutamide (four 40 mg soft capsules) as a single oral daily dose.
Medical castration with a luteinising hormone-releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated.
If a patient misses taking enzalutamide at the usual time, the prescribed dose should be taken as close as possible to the usual time. If a patient misses a dose for a whole day, treatment should be resumed the following day with the usual daily dose.
If a patient experiences a ≥Grade 3 toxicity or an intolerable adverse reaction, dosing should be withheld for one week or until symptoms improve to ≤Grade 2, then resumed at the same or a reduced dose (120 mg or 80 mg) if warranted.
Concomitant use with strong CYP2C8 inhibitors: The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily. If co-administration of the strong CYP2C8 inhibitor is discontinued, the enzalutamide dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor (see Interactions).
Elderly: No dose adjustment is necessary for elderly patients (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment (see Pharmacology: Pharmacokinetics under Actions). Caution is advised in patients with severe renal impairment or end-stage renal disease (see Precautions).
Hepatic impairment: No dose adjustment is necessary for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C, respectively) (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: There is no relevant use of enzalutamide in the paediatric population in the indication of treatment of adult men with CRPC and mHSPC.
Method of administration: Enzalutamide is for oral use. The soft capsules should not be chewed, dissolved or opened but should be swallowed whole with water, and can be taken with or without food.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement